799 records found.
Dec 08, 2019
First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
Dec 07, 2019
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019
Dec 06, 2019
FDA Approves Amgen's AVSOLA(TM) (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
Dec 06, 2019
Global Monoclonal Antibody Partnering Terms and Agreements Directory 2019
Dec 05, 2019
Cancer Treatment Centers of America Continues Pioneering Efforts in Immuno-Oncology; Doses First Patient in Novel Immunotherapy Clinical Trial
Dec 05, 2019
Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder
Dec 02, 2019
BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference
Dec 02, 2019
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Nov 29, 2019
World Migraine Therapeutics Market Study 2019-2024 - Triptans Projected to Grow at a Healthy CAGR
Nov 15, 2019
RemeGen, Ltd. Announces Positive Results from Phase IIb Clinical Trial in Systemic Lupus Erythematosus
Nov 15, 2019
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Nov 14, 2019
I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China
Nov 12, 2019
Regeneron Announces Upcoming Investor Conference Presentations
Nov 12, 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
Nov 12, 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Nov 11, 2019
Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting
Nov 11, 2019
TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Nov 11, 2019
Global Urothelial Carcinoma Market Insights, Epidemiology and Market Forecasts Report 2019-2028
Nov 11, 2019
Lupus Research Alliance Response to Positive Data from Phase 3 Anifrolumab Trial Presented at 2019 ACR/ARP Annual Meeting
Nov 08, 2019
Latest Developments in the Interleukin-2 (IL-2) Research and Development, 2019 Report

Pages